Retatrutide

In clinical trials

Also known as: LY3437943, "Reta"

Category: Weight & metabolic

Sold as:

Ameano Peptides: AMP-3P

Nexaph: NXP-3P

Investigational triple agonist of GLP-1, GIP and glucagon receptors. Phase 2 trials showed very large weight loss.

What it's used for

Typical dose: Trial protocols started at 2 mg weekly and escalated every 4 weeks toward 8 to 12 mg weekly. No approved dose exists.
How often: Once weekly
Route: Subcutaneous injection
Cycle length: Trial durations were 48 weeks or longer

These two suggestions come from this site’s owner and from what people commonly report. Neither is a trial protocol, and neither has been tested in a study. Talk to a clinician before changing what you are doing.
Split the weekly dose in two. Trials gave the whole amount in one injection a week. If you have been steady at a dose and progress has flattened, one approach is to take the same weekly total as two injections a few days apart — for example 4 mg weekly given as 2 mg twice a week. The amount over the week does not change, only how it is spread.
Run cagrilintide alongside it. Cagrilintide is an amylin analog, so it works through a different receptor than retatrutide’s GLP-1, GIP and glucagon targets, and the two are sold together as a blend. Note that the trials pairing cagrilintide with another drug used semaglutide, not retatrutide, so this combination is community practice rather than something that has been studied.

Important: Not approved. Anything sold outside clinical trials is unregulated and purity cannot be assumed.

Reta/Cagri Blend: Retatrutide 12.5 mg + Cagrilintide 2.5 mg (Ameano Peptides)